Your browser doesn't support javascript.
loading
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Procopio, G; Verzoni, E; Bracarda, S; Ricci, S; Sacco, C; Ridolfi, L; Porta, C; Miceli, R; Zilembo, N; Bajetta, E.
Affiliation
  • Procopio G; Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian, Milan 1-20133, Italy. giuseppe.procopio@istitutotumori.mi.it
Br J Cancer ; 104(8): 1256-61, 2011 Apr 12.
Article in En | MEDLINE | ID: mdl-21448165
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Benzenesulfonates / Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Interleukin-2 / Kidney Neoplasms Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2011 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Benzenesulfonates / Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Interleukin-2 / Kidney Neoplasms Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2011 Document type: Article Affiliation country: